ES2898698T3 - Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK) - Google Patents

Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK) Download PDF

Info

Publication number
ES2898698T3
ES2898698T3 ES17701785T ES17701785T ES2898698T3 ES 2898698 T3 ES2898698 T3 ES 2898698T3 ES 17701785 T ES17701785 T ES 17701785T ES 17701785 T ES17701785 T ES 17701785T ES 2898698 T3 ES2898698 T3 ES 2898698T3
Authority
ES
Spain
Prior art keywords
alkyl
heterocycle
carbocycle
independently selected
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17701785T
Other languages
English (en)
Spanish (es)
Inventor
Ii Leon M Smith
Vladimir Ladziata
Indawati Delucca
Donald Pinto
Michael J Orwat
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
Wu Yang
Scott A Shaw
Peter W Glunz
Manoranjan Panda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2898698T3 publication Critical patent/ES2898698T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES17701785T 2016-01-13 2017-01-13 Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK) Active ES2898698T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13
PCT/US2017/013323 WO2017123860A1 (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Publications (1)

Publication Number Publication Date
ES2898698T3 true ES2898698T3 (es) 2022-03-08

Family

ID=57907009

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17701785T Active ES2898698T3 (es) 2016-01-13 2017-01-13 Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK)

Country Status (28)

Country Link
US (2) US10611776B2 (US07585860-20090908-C00112.png)
EP (2) EP3954681A1 (US07585860-20090908-C00112.png)
JP (2) JP6976953B2 (US07585860-20090908-C00112.png)
KR (1) KR20180097749A (US07585860-20090908-C00112.png)
CN (1) CN108699038B (US07585860-20090908-C00112.png)
AR (1) AR107354A1 (US07585860-20090908-C00112.png)
AU (2) AU2017206820B2 (US07585860-20090908-C00112.png)
BR (1) BR112018013780B1 (US07585860-20090908-C00112.png)
CA (1) CA3010900A1 (US07585860-20090908-C00112.png)
CL (1) CL2018001899A1 (US07585860-20090908-C00112.png)
CO (1) CO2018008173A2 (US07585860-20090908-C00112.png)
CY (1) CY1124858T1 (US07585860-20090908-C00112.png)
EA (1) EA036172B1 (US07585860-20090908-C00112.png)
ES (1) ES2898698T3 (US07585860-20090908-C00112.png)
HR (1) HRP20211888T1 (US07585860-20090908-C00112.png)
HU (1) HUE057455T2 (US07585860-20090908-C00112.png)
IL (1) IL260448B (US07585860-20090908-C00112.png)
LT (1) LT3402790T (US07585860-20090908-C00112.png)
MA (2) MA43862A (US07585860-20090908-C00112.png)
MX (2) MX2018008219A (US07585860-20090908-C00112.png)
PL (1) PL3402790T3 (US07585860-20090908-C00112.png)
PT (1) PT3402790T (US07585860-20090908-C00112.png)
RS (1) RS62690B1 (US07585860-20090908-C00112.png)
SG (1) SG11201805927YA (US07585860-20090908-C00112.png)
SI (1) SI3402790T1 (US07585860-20090908-C00112.png)
TW (1) TWI730032B (US07585860-20090908-C00112.png)
UY (1) UY37073A (US07585860-20090908-C00112.png)
WO (1) WO2017123860A1 (US07585860-20090908-C00112.png)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103990A1 (es) 2015-01-09 2017-06-21 Bristol Myers Squibb Co Ureas cíclicas como inhibidoras de rock
WO2016144936A1 (en) 2015-03-09 2016-09-15 Bristol-Myers Squibb Company Lactams as inhibitors of rock
ES2821969T3 (es) 2016-01-13 2021-04-28 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diazaespiro-[4.5]-decano
EA034904B1 (ru) 2016-01-13 2020-04-03 Грюненталь Гмбх Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро-[4.5]-декана
RS60307B1 (sr) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
UY37073A (es) 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
RS60315B1 (sr) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero-)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
WO2017205709A1 (en) 2016-05-27 2017-11-30 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
ES2814325T3 (es) 2016-07-07 2021-03-26 Bristol Myers Squibb Co Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
ES2829550T3 (es) 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
CN109689639B (zh) 2016-07-07 2022-02-18 百时美施贵宝公司 作为rock抑制剂的螺内酰胺
WO2018102325A1 (en) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors
ES2894128T3 (es) * 2017-07-12 2022-02-11 Bristol Myers Squibb Co Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
KR102680164B1 (ko) 2017-07-12 2024-07-01 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 페닐아세트아미드
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
WO2019089868A1 (en) 2017-11-03 2019-05-09 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
IL277963B1 (en) * 2018-04-17 2024-05-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of using them
JPWO2023085369A1 (US07585860-20090908-C00112.png) 2021-11-11 2023-05-19
WO2024013736A1 (en) * 2022-07-12 2024-01-18 Adama Makhteshim Ltd. Process for preparing substituted benzamides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460477A (zh) * 2006-06-08 2009-06-17 宇部兴产株式会社 侧链具有螺环结构的新型吲唑衍生物
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
RU2457203C2 (ru) * 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
AU2008340601A1 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Process for the preparation of 6-substituted-1-(2H)-isoquinolinones
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
JP6488239B2 (ja) 2013-01-18 2019-03-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としてのフタラジノンおよびイソキノリノン
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
JP6423372B2 (ja) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体
ES2633987T3 (es) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
EP3183248B1 (en) 2014-08-21 2020-11-11 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
AR103990A1 (es) 2015-01-09 2017-06-21 Bristol Myers Squibb Co Ureas cíclicas como inhibidoras de rock
WO2016144936A1 (en) 2015-03-09 2016-09-15 Bristol-Myers Squibb Company Lactams as inhibitors of rock
UY37073A (es) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
WO2017205709A1 (en) 2016-05-27 2017-11-30 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
ES2829550T3 (es) 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
ES2814325T3 (es) 2016-07-07 2021-03-26 Bristol Myers Squibb Co Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
CN109689639B (zh) 2016-07-07 2022-02-18 百时美施贵宝公司 作为rock抑制剂的螺内酰胺
WO2018102325A1 (en) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors

Also Published As

Publication number Publication date
MX2021005311A (es) 2021-06-23
AU2017206820A1 (en) 2018-08-23
CO2018008173A2 (es) 2018-08-21
JP7268116B2 (ja) 2023-05-02
MX2018008219A (es) 2018-09-07
CA3010900A1 (en) 2017-07-20
EP3402790A1 (en) 2018-11-21
JP2019509978A (ja) 2019-04-11
AU2021221872A1 (en) 2021-09-23
SG11201805927YA (en) 2018-08-30
TW201726619A (zh) 2017-08-01
CL2018001899A1 (es) 2018-11-09
LT3402790T (lt) 2021-12-10
RS62690B1 (sr) 2021-12-31
EP3954681A1 (en) 2022-02-16
CY1124858T1 (el) 2022-11-25
SI3402790T1 (sl) 2022-01-31
CN108699038A (zh) 2018-10-23
EP3402790B1 (en) 2021-10-06
US10829501B2 (en) 2020-11-10
HUE057455T2 (hu) 2022-05-28
CN108699038B (zh) 2021-04-16
US10611776B2 (en) 2020-04-07
KR20180097749A (ko) 2018-08-31
MA55633A (fr) 2022-02-16
BR112018013780A2 (pt) 2018-12-11
EA036172B1 (ru) 2020-10-09
EA201891557A1 (ru) 2019-01-31
HRP20211888T1 (hr) 2022-03-04
US20200131200A1 (en) 2020-04-30
JP6976953B2 (ja) 2021-12-08
MA43862A (fr) 2021-06-02
BR112018013780B1 (pt) 2023-12-19
PT3402790T (pt) 2021-11-22
AU2017206820B2 (en) 2021-06-17
IL260448B (en) 2020-09-30
US20190016735A1 (en) 2019-01-17
AR107354A1 (es) 2018-04-18
JP2022024019A (ja) 2022-02-08
TWI730032B (zh) 2021-06-11
UY37073A (es) 2017-07-31
PL3402790T3 (pl) 2022-01-24
WO2017123860A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
ES2898698T3 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK)
EP3652168B1 (en) 5-membered and bicyclic heterocyclic amides as inhibitors of rock
US9902702B2 (en) Spirocycloheptanes as inhibitors of rock
ES2814325T3 (es) Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
ES2886650T3 (es) Derivados de indazol como antagonistas de integrina alfaV
ES2951212T3 (es) Fenilacetamidas como inhibidores de ROCK
TW201906834A (zh) 人類免疫不全病毒複製之抑制劑
ES2894128T3 (es) Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca
ES2698960T3 (es) Compuestos de 2-aminopiridina
JP2022551299A (ja) Brd4阻害活性を有する化合物、その調製方法および用途
CA3203922A1 (en) Enzyme inhibitors